Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms

[1]  Pairunyar Nakavachara,et al.  Bone Mineral Density and Serum 25OHD in Children and Adolescents With Juvenile Idiopathic Arthritis , 2022, Clinical pediatrics.

[2]  S. Al‐Mayouf,et al.  Epidemiology and demographics of juvenile idiopathic arthritis in Africa and Middle East , 2021, Pediatric Rheumatology.

[3]  M. Abdelsalam,et al.  Predictors of decreased bone mineral density in childhood systemic lupus erythematosus: possible role of osteoprotegerin gene polymorphisms , 2021, Journal of pediatric endocrinology & metabolism : JPEM.

[4]  Radwa Helmy Shalaby,et al.  P013 Serum osteoprotegerin and RANKL in patients with Juvenile Idiopathic Arthritis and their correlation with bone mineral density , 2021, Rheumatology.

[5]  S. Al‐Mayouf,et al.  Cumulative Damage in Juvenile Idiopathic Arthritis: A Multicenter Study From the Pediatric Rheumatology Arab Group , 2020, Arthritis care & research.

[6]  Ayman Abu Hammad,et al.  Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus , 2019, Lupus.

[7]  D. Foell,et al.  Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. , 2019, The Lancet. Child & adolescent health.

[8]  N. Ruperto,et al.  The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) , 2018, Rheumatology International.

[9]  Z. Hussein,et al.  The pattern of juvenile idiopathic arthritis; a retrospective Egyptian study , 2018 .

[10]  A. Cardona,et al.  [Low bone mineral density in juvenile idiopathic arthritis: Prevalence and related factors]. , 2017 .

[11]  A. Ravelli,et al.  Clinical outcome measures in juvenile idiopathic arthritis , 2016, Pediatric Rheumatology.

[12]  K. Karavanaki,et al.  Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis , 2016, Osteoporosis International.

[13]  I. Al-Zakwani,et al.  Epidemiology of juvenile idiopathic arthritis in Oman , 2015, Pediatric Rheumatology.

[14]  J. Śanchez-Corona,et al.  Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report , 2015, Journal of immunology research.

[15]  R. Dagher,et al.  Juvenile idiopathic arthritis: a single center Lebanese study , 2014, Pediatric Rheumatology.

[16]  S. Rostom,et al.  Bone Mineral Density in Moroccan Patients with Juvenile Idiopathic Arthritis , 2014 .

[17]  M. Cerinic,et al.  Bone mass and quality in patients with juvenile idiopathic arthritis: longitudinal evaluation of bone-mass determinants by using dual-energy x-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasonography , 2014, Arthritis Research & Therapy.

[18]  Francis Guillemin,et al.  Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. , 2014, Joint, bone, spine : revue du rhumatisme.

[19]  S. Rostom,et al.  Effect of body composition on bone mineral density in Moroccan patients with juvenile idiopathic arthritis , 2014, The Pan African medical journal.

[20]  S. Rahman,et al.  Bone Mineral Density in Children with Juvenile Idiopathic Arthritis: A Hospital Based Study , 2013 .

[21]  E. Alkady,et al.  Early predictors of increased bone resorption in juvenile idiopathic arthritis: OPG/RANKL ratio, as a key regulator of bone metabolism , 2011 .

[22]  D. Symmons,et al.  Bone Health in Adult Men and Women with a History of Juvenile Idiopathic Arthritis , 2011, The Journal of Rheumatology.

[23]  Bin Huang,et al.  American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis , 2011, Arthritis care & research.

[24]  K. Godang,et al.  Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study , 2010, Pediatric rheumatology online journal.

[25]  A. Rybi-Szumińska,et al.  Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children , 2010, Pediatric Nephrology.

[26]  J. Yazdany,et al.  Bone health in systemic lupus erythematosus , 2009, Current rheumatology reports.

[27]  F. Zaccardi,et al.  Association Between Osteoprotegerin G1181C and T245G Polymorphisms and Diabetic Charcot Neuroarthropathy , 2009, Diabetes Care.

[28]  R. Misra,et al.  Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis , 2009, Rheumatology International.

[29]  Alberto Martini,et al.  Development and validation of a composite disease activity score for juvenile idiopathic arthritis. , 2009, Arthritis and rheumatism.

[30]  L. Bo,et al.  Bone mineral density in patients with Juvenile Rheumatoid Arthritis , 2008, Pediatric Rheumatology Online Journal.

[31]  R. Misra,et al.  Elevated serum receptor activator of NFκB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis , 2008, Clinical Rheumatology.

[32]  E. Bonfá,et al.  Osteoprotegerin/RANKL system imbalance in active polyarticular‐onset juvenile idiopathic arthritis: a bone damage biomarker? , 2008, Scandinavian journal of rheumatology.

[33]  U. Andersson,et al.  Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. , 2007, The Journal of rheumatology.

[34]  R. Saurenmann,et al.  Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. , 2007, Arthritis and rheumatism.

[35]  C. Langman,et al.  RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. , 2007, Arthritis and rheumatism.

[36]  A. Bideci,et al.  Osteoprotegerin and RANKL Serum Levels and Their Relationship with Serum Ghrelin in Children with Chronic Renal Failure and on Dialysis , 2007, Nephron Clinical Practice.

[37]  M. Hakala,et al.  Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis , 2007, Scandinavian journal of rheumatology.

[38]  A. Bakr,et al.  LOW BONE MASS IN CHILDREN WITH MALIGNANT LYMPHOMA , 2007, Pediatric hematology and oncology.

[39]  S. van der Linden,et al.  The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. , 2006, Arthritis and rheumatism.

[40]  L. Bachrach.  Measuring Bone Mass in Children: Can We Really Do It? , 2006, Hormone Research in Paediatrics.

[41]  Y. Al-Tonbary,et al.  Low turnover bone disease in Egyptian children with acute leukemia , 2005, Hematology.

[42]  A. Martini,et al.  Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[43]  B. Evans,et al.  Skeletal morbidity in childhood acute lymphoblastic leukaemia , 2005, Clinical endocrinology.

[44]  M. de Martino,et al.  Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. , 2005, Rheumatology.

[45]  E. Giannini,et al.  Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. , 2004, The Journal of rheumatology.

[46]  L. Hofbauer,et al.  Osteoprotegerin gene polymorphisms in men with coronary artery disease. , 2004, The Journal of clinical endocrinology and metabolism.

[47]  M. Brandi,et al.  Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? , 2004, The Journal of rheumatology.

[48]  U. Lerner.  NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION. , 2004, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[49]  M. Suarez‐Almazor,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[50]  D. Cocchi,et al.  Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis , 2004, Clinical endocrinology.

[51]  P. Woo,et al.  Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). , 2003, Rheumatology.

[52]  P. Vähäsalo,et al.  Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study , 2003, Annals of the rheumatic diseases.

[53]  L. Hofbauer,et al.  The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[54]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[55]  D. Murray,et al.  Rheumatoid arthritis synovial macrophage–osteoclast differentiation is osteoprotegerin ligand‐dependent , 2000, The Journal of pathology.

[56]  P. Mantyh,et al.  Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.

[57]  T. Bateman,et al.  Osteoprotegerin mitigates tail suspension-induced osteopenia. , 2000, Bone.

[58]  J. Hopper,et al.  Genetic determinants of bone mass in adults. A twin study. , 1987, The Journal of clinical investigation.

[59]  Gisela Díaz-Cordovés Rego,et al.  [Low bone mineral density in juvenile idiopathic arthritis: Prevalence and related factors]. , 2017, Anales de pediatria.

[60]  A. Bakkaloğlu,et al.  The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. , 2011, Clinical and experimental rheumatology.

[61]  N. Pilipović,et al.  [Bone mineral density in patients with juvenile idiopathic arthritis]. , 2009, Srpski arhiv za celokupno lekarstvo.

[62]  Chen Shunle.  The significance of the RANKL and OPG gene expression in the initial systemic lupus erythematosus patients , 2009 .

[63]  J. Bilezikian,et al.  Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. , 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.